Biogen’s stock could fall 10% on new Alzheimer’s drug data this week, top analyst says

Biogen’s stock could fall as much as 10% once it releases new data this week on its Alzheimer’s drug, analyst Brian Skorney says. “We do not think that data validates anything near receiving approval from the FDA,” he adds.